Open AccessTreatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice
Author(s) -
Volker Schmitz,
Miroslaw Kornek,
Tobias Hilbert,
C. Dzienisowicz,
E. Raskopf,
Christian Rabe,
Tilman Sauerbruch,
Cheng Qian,
Wolfgang H. Caselmann
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i28.4332
Subject(s) - angiogenesis , cancer research , vascular endothelial growth factor , human umbilical vein endothelial cell , endothelial stem cell , in vivo , cell culture , cell growth , biology , immunology , medicine , in vitro , biochemistry , genetics , microbiology and biotechnology , vegf receptors
Tumor angiogenesis has been shown to be promoted by vascular endothelial growth factor (VEGF) via stimulating endothelial cell proliferation, migration, and survival. Blockade of VEGF signaling by different means has been demonstrated to result in reduced tumor growth and suppression of tumor angiogenesis in distinct tumor entities. Here, we tested a recombinant adenovirus, AdsFlt1-3, that encodes an antagonistically acting fragment of the VEGF receptor 1 (Flt-1), for systemic antitumor effects in pre-established subcutaneous CRC tumors in mice.